Industry News

The latest news from the clinical trials industry.

News Powered By:

- a collaborative partner.


 


BioMarin to acquire Prosensa for $680M


CenterWatch News Online Headlines : November 25, 2014 2:30 am : Centerwatch

BioMarin Pharmaceutical, based in San Rafael, Calif., will acquire Prosensa for $17.75 per share, for a total up-front consideration of approximately $680 million. In addition, two approximately $80 million contingent milestones are payable for the approval of drisapersen in the U.S. no later than May 15, 2016, and Europe no later than Feb. 15, 2017, respectively.



CytRx announces partial clinical hold affecting aldoxorubicin clinical trials


CenterWatch News Online Headlines : November 24, 2014 8:58 am : Centerwatch

CytRx, a biopharmaceutical R&D company specializing in oncology, has received notice from the FDA that its clinical trials for aldoxorubicin have been placed on partial clinical hold. All currently enrolled patients can continue receiving aldoxorubicin treatment, or comparator drugs, as per study protocols, but no new patients can be enrolled until the clinical hold is lifted.



Report: 80% of pharma outsource some of their government reimbursement budgets


CenterWatch News Online Headlines : November 24, 2014 8:53 am : Centerwatch

Eighty percent of surveyed pharma companies outsource some portion of their government reimbursement budgets, including third-party audits that can help companies remain compliant to changing industry guidelines, according to Cutting Edge Information, a Research Triangle Park, N.C.-based pharmaceutical business intelligence provider.



Cell Therapy Catapult, partners launch U.K. database of research funding


CenterWatch News Online Headlines : November 24, 2014 8:50 am : Centerwatch

The Cell Therapy Catapult, focused on the development of the U.K. cell therapy industry, has collaborated with the U.K. Regenerative Medicine Platform, the Knowledge Transfer Network and the Association of Medical Research Charities to develop a database of U.K. cell therapy research funding.



SEC suspends trading in companies touting Ebola-related prevention/treatment operations


CenterWatch News Online Headlines : November 24, 2014 8:49 am : Centerwatch

The Securities and Exchange Commission has suspended trading in four companies that claim to be developing products or services in response to the Ebola outbreak, citing a lack of publicly available information about the companies’ operations.


« Page 1, 2, 3490, »